Farletuzumab companion diagnostic - Fujirebio Diagnostics

Drug Profile

Farletuzumab companion diagnostic - Fujirebio Diagnostics

Alternative Names: CA125 II assay - Fujirebio Diagnostics; CA125 II companion diagnostic; Lumipulse® G CA125-II assay - Fujirebio Diagnostics; MORAb-003 companion diagnostic

Latest Information Update: 14 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Fujirebio Diagnostics
  • Class Diagnostic agents
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Ovarian cancer

Most Recent Events

  • 05 Sep 2017 Fujirebio Diagnostics and Morphotek enter into a collaboration agreement to develop and commercialise Farletuzumab companion diagnostic
  • 05 Sep 2017 Clinical trials in Ovarian cancer (Diagnosis) in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top